A combination comprising, spatially separate from one another, a first component and a second component, where the first component comprises crosslinkable albumin and the second component comprises a polymer, wherein non-terminal monomer units of the polymer comprise at least partially, more particularly only partially, an albumin-crosslinking group. Additionally disclosed is a reaction product obtainable by means of the combination, to a medical device, to a medicinal product for innovative therapies, to a kit, to a discharge apparatus, and to a functionalized hyaluronic acid.

Methods are disclosed for dissecting a mucosa and a submucosa from a muscularis propria from a region of an organ of a subject, wherein the organ is not the esophagus. In some embodiments, the organ is in the gastrointestinal tract. These methods include injecting submucosally into the organ of the subject a pharmaceutical composition comprising an extracellular matrix (ECM) hydrogel to form a cushion between the submucosa and the underlying muscularis propria at the region of the organ, wherein the ECM hydrogel has the following characteristics: a) a time to 50% gelation of less than 30 minutes at a temperature of about 37° C.; b) a flow viscosity suitable for infusion into the organ; and c) a stiffness of about 10 to about 400 Pascal (Pa).

A problem addressed by the present invention is to provide a method for producing primitive gut tube cells from endothermal cells that have been induced to differentiate from pluripotent stein cells, wherein the method allows the production of pancreatic β cells of high quality. The present invention provides a method for producing primitive gut tube (PGT) cells comprising a step of culturing, in the absence of a bone morphogenetic protein (BMP) signaling inhibitor, endodermal cells that have been induced to differentiate from pluripotent stem cells.

A problem addressed by the present invention is to provide a method for producing primitive gut tube cells from endothermal cells that have been induced to differentiate from pluripotent stein cells, wherein the method allows the production of pancreatic β cells of high quality. The present invention provides a method for producing primitive gut tube (PGT) cells comprising a step of culturing, in the absence of a bone morphogenetic protein (BMP) signaling inhibitor, endodermal cells that have been induced to differentiate from pluripotent stem cells.

An implantable medical product and method of use for substantially reducing or eliminating harsh biological responses associated with conventionally implanted medical devices, including inflammation, infection and thrombogenesis, when implanted in in a body of a warm blooded mammal. The bioremodelable pouch structure is configured and sized to receive, encase and retain an electrical medical device therein and to allow such device to be inserted into the internal region or cavity of the pouch structure; with the pouch structure formed from either: (a) first and second sheets, or (b) a single sheet having first and second sheet portions. After receiving the electrical device, the edges around the opening are closed by suturing or stapling. The medical device encased by the bioremodelable pouch structure effectively improves biological functions by promoting tissue regeneration, modulated healing of adjacent tissue or growth of new tissue when implanted in the body of the mammal.

An implantable medical product and method of use for substantially reducing or eliminating harsh biological responses associated with conventionally implanted medical devices, including inflammation, infection and thrombogenesis, when implanted in in a body of a warm blooded mammal. The bioremodelable pouch structure is configured and sized to receive, encase and retain an electrical medical device therein and to allow such device to be inserted into the internal region or cavity of the pouch structure; with the pouch structure formed from either: (a) first and second sheets, or (b) a single sheet having first and second sheet portions. After receiving the electrical device, the edges around the opening are closed by suturing or stapling. The medical device encased by the bioremodelable pouch structure effectively improves biological functions by promoting tissue regeneration, modulated healing of adjacent tissue or growth of new tissue when implanted in the body of the mammal.

The present disclosure relates to the use of autologous fecal samples obtained from a subject for use in prevention and/or treatment of microbial dysbiosis in the gastrointestinal tract in said subject and to related pharmaceutical compositions for oral administration. The disclosed autologous fecal samples are useful for treatment of microbial dysbiosis in the gastrointestinal tract associated with medical treatment and/or various indications, including chronic disease and infectious disease, for example Clostridium difficile infection.

The present disclosure relates to the use of autologous fecal samples obtained from a subject for use in prevention and/or treatment of microbial dysbiosis in the gastrointestinal tract in said subject and to related pharmaceutical compositions for oral administration. The disclosed autologous fecal samples are useful for treatment of microbial dysbiosis in the gastrointestinal tract associated with medical treatment and/or various indications, including chronic disease and infectious disease, for example Clostridium difficile infection.

The instant disclosure relates to methods for converting mammalian definitive endoderm (DE) cells into specific tissue(s) or organ(s) through directed differentiation. In particular, the disclosure relates to formation of esophageal tissue and/or organoids formed from differentiated definitive endoderm.

The instant disclosure relates to methods for converting mammalian definitive endoderm (DE) cells into specific tissue(s) or organ(s) through directed differentiation. In particular, the disclosure relates to formation of esophageal tissue and/or organoids formed from differentiated definitive endoderm.